PTPRC and neoplasm: In order to understand which immune cell subsets are affected by the combination therapy, analysis of the tumor immune transcriptome was performed by single-cell RNA sequencing (scRNA-seq) of CD45+ tumor-infiltrating cells pooled from MC38 control and treated tumors.